Win a $10,000 Education Fund for Your Miracle Child

PARSIPPANY, N.J., April 9, 2008 /PRNewswire/ -- If you are a parent who has successfully given birth using Ferring Pharmaceuticals' fertility products, you can win a $10,000 education fund to support your child's future. Eleven other education fund prizes will also be awarded. To be eligible, all you need to do is write a brief essay. The topic is: If I Knew Then What I Know Now, explaining what advice you would give to other women who are just beginning their journey to parenthood and how you would describe your success using BRAVELLE(R) (urofollitropin for injection, purified) and/or MENOPUR (R) (menotropins for injection, USP) as part of your treatment plan.

Ferring's My Little Miracle Essay Contest is open to women who have been successfully treated with BRAVELLE(R) and/or MENOPUR(R). The contest celebrates the miracle of birth for parents who have faced infertility, and carries on Ferring's tradition of supporting patients by offering education funds for the winners' children.

Ferring is also awarding a $2,500 education fund to the runner up and $500 each to 10 honorable mention winners. Since announcing the first contest in 2004, Ferring has awarded $85,000 in education funds.

Essays should not exceed 2,000 words. They must be written in English, include the entrant's name, address, phone number and age, as well as the child(ren)'s name(s) and age(s), and be submitted with a contest application and labeled digital photo. Entries must be postmarked by August 30, 2008. Winners will be announced at the 64th Annual Meeting of the American Society for Reproductive Medicine (ASRM), November 8-12, 2008.

For more details and a contest application, visit www.ferringfertility.com or www.ferringusa.com or call (203) 762-8833 and ask for the My Little Miracle Essay Contest representative.

BRAVELLE(R) and MENOPUR (R), like all gonadotropins, are potent substances capable of causing mild to severe adverse reactions, including OHSS (incidence of 6.0% and 3.8%, respectively), with or without pulmonary or vascular complications, in women undergoing therapy for infertility.

The treatments are marketed by Ferring Pharmaceuticals Inc., a world leader in naturally occurring protein hormones. Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe these medications. Like other products for ovarian stimulation, treatment with BRAVELLE(R) and/or MENOPUR (R) may result in multiple gestations.

About Ferring Pharmaceuticals

Ferring Pharmaceuticals, part of the Ferring Group, a privately owned, international pharmaceutical company, manufactures and markets the largest family of fertility treatments of any manufacturer in the U.S. The Company markets BRAVELLE(R), MENOPUR(R), REPRONEX(R) (menotropins for injection, USP), NOVAREL(R) (chorionic gonadotropin for injection, USP) and ENDOMETRIN(R) (progesterone) Vaginal Insert, 100 mg in the U.S. to infertility specialists and their patients. Ferring also offers the Q-CAP(TM), the first and only needle-free reconstitution device, for use with its fertility treatments.

Ferring's line of orthopaedic and urology products includes EUFLEXXA(TM), hyaluronic acid for pain from osteoarthritis in the knee. Other products include: ACTHREL(R) (corticorelin ovine triflutate for injection) for the differential diagnosis of Cushing's syndrome; DESMOPRESSIN ACETATE in injectable and rhinal tube forms for the treatment of diabetes insipidus and primary nocturnal enuresis; and PROSED(R)/DS for the relief of discomfort of the lower urinary tract.

The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/ gynecology and infertility. For more information, call 888-337-7464 or visit www.ferringusa.com or www.ferringfertility.com.

Please contact Christine Stroup for full prescribing information.